← 產業報告目錄
Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Size, Share & Trends Analysis by Disease (Neurological Disorders and Dystrophies, Cardiac disorders, Retinal Eye Disease, Metabolic Disorders, Liver disease, Others), Products and Services (Disease Model, Reprogramming service, Differentiation service, Screening service, Characterization service, Others), and Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-04頁數 180報告編號 INSIGHTACE-ca1ca84a6d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market is positioned for steady expansion, with a projected CAGR of 11.2% from 2024 to 2031.
Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model encompasses a pivotal tool in biomedical research, particularly for preclinical disease modelling and drug development. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the mounting emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Snapshot
Chapter 4. Global Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Disease Estimates & Trend Analysis
5.1. By Disease, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Disease:
5.2.1. Neurological Disorders and Dystrophies
5.2.2. Cardiac disorders
5.2.3. Retinal Eye Disease
5.2.4. Metabolic Disorders
5.2.5. Liver disease
5.2.6. Others
Chapter 6. Market Segmentation 2: By Product And Services Estimates & Trend Analysis
6.1. By Product And Services & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Product And Services:
6.2.1. Disease Model
6.2.2. Reprogramming service
6.2.3. Differentiation service
6.2.4. Screening service
6.2.5. Characterization service
6.2.6. Others
Chapter 7. Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) estimates and forecasts By Disease, 2024-2031
7.1.2. North America Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) estimates and forecasts By Product And Services, 2024-2031
7.1.3. North America Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Disease, 2024-2031
7.2.2. Europe Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Product And Services, 2024-2031
7.2.3. Europe Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Disease, 2024-2031
7.3.2. Asia Pacific Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Product And Services, 2024-2031
7.3.3. Asia Pacific Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Disease, (US$ Million) 2024-2031
7.4.2. Latin America Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Product And Services, (US$ Million) 2024-2031
7.4.3. Latin America Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) by country, 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Disease, (US$ Million) 2024-2031
7.5.2. Middle East & Africa Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) By Product And Services, (US$ Million) 2024-2031
7.5.3. Middle East & Africa Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market revenue (US$ Million) by country, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Axol Bioscience Ltd
8.2.2. DefiniGEN
8.2.3. REPROCELL
8.2.4. The Jackson Laboratory
8.2.5. Creative Biolabs
8.2.6. Cyagen
8.2.7. FUJIFILM Cellular Dynamics
8.2.8. ElevateBio
8.2.9. Bio-Techne
8.2.10. BPS Bioscience, Inc.
8.2.11. Catalent, Inc
8.2.12. Ncardia
8.2.13. NEXEL Co
8.2.14. Evotec's
8.2.15. iXCells Biotechnologies
8.2.16. Elixirgen
8.2.17. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們